How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
To determine the magnitude and mechanisms of response to Medicare Part D cost sharing by low-income subsidy (LIS) recipients using oral hypoglycemic agents (OHAs) and statins.



Medicare data for a 5 percent random sample of beneficiaries with diabetes enrolled in fee-for-service Part D drug plans in 2008.



We evaluated the impact of differences between generic and brand cost sharing rates among cohorts of LIS and non-LIS recipients to determine if wider price spreads increased the generic dispensing rate (GDR) and reduced total drug use and cost.



We found little association between cost sharing and aggregate OHA and statin use. In adjusted analyses, non-LIS beneficiaries who paid 46 percent of total OHA costs had 2.5 percent fewer OHA days supply than full benefit dual eligibles who paid just 5 percent of their therapy costs. For statins, the difference in days supply between those facing the lowest and highest cost sharing was 4.6 percent. Higher cost sharing was associated with filling fewer but larger prescriptions for both generics and brands.



Higher generic and brand copays had little association with OHA and statin use among LIS recipients. This implies that modest changes in required cost sharing for these medicines would have very little substantive impact on generic dispensing or utilization patterns among LIS recipients and thus would have little effect on total program spending. At the same time, any increases in out-of-pocket costs would be expected to shift costs and place greater financial burden on low-income beneficiaries, particularly those in poor health.
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD.
Bruce
B
Stuart
Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD.
Franklin B
FB
Hendrick
Doctoral Program in Gerontology, University of Maryland Baltimore County, Baltimore, MD.
Jing
J
Xu
PhRMA, Washington, DC.
J Samantha
JS
Dougherty
D017047:Cost Sharing / Q000191:economics*; D003920:Diabetes Mellitus / Q000188:drug therapy; D016527:Drug Costs; D005102:Health Expenditures; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054524:Medicare Part D / Q000191:economics*; D011203:Poverty / Q000191:economics*; D014481:United States
D007004:Hypoglycemic Agents

LIS
; Medicare Part D; cost sharing; oral hypoglycemic agents; statins